| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
BioCardia Inc (NASDAQ:BCDA) shares are trading higher by 95% to $4.30 during Thursday’s session after the FDA cleared the company to market its Morph DNA Steerable Introducer product family.
What Happened: The product family is designed to facilitate the introduction of medical instruments, such as catheters and guidewires, into the peripheral vasculature and heart chambers during various cardiovascular and interventional procedures.
BioCardia’s CEO, Peter Altman, highlighted that previous versions of the Morph product have been used in approximately 12,000 procedures, and the new Morph DNA family is anticipated to bring additional value to physicians and their patients.
BioCardia says the company initially developed this product to enhance its own cell therapy procedures, but it is now expected to improve outcomes in a variety of other advanced interventional procedures as well.
Read Also: Nvidia ETFs Split In Pre-Market After Jensen Huang-Led Chip Giant Exceeds Q2 Expectations
Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, in BioCardia’s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from Benzinga Pro, BCDA has a 52-week high of $23.25 and a 52-week low of $1.96.
Posted In: BCDA
